WCN25-1188 THE USEFULNESS OF URINARY N-ACETYL- β-D-GLUCOSAMINIDASE-CREATININE RATIO AS THE BIOMARKER TO DECIDE LONG-TERM USE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR IN DIABETIC KIDNEY DISEASE

WCN25-1188 THE USEFULNESS OF URINARY N-ACETYL- β-D-GLUCOSAMINIDASE-CREATININE RATIO AS THE BIOMARKER TO DECIDE LONG-TERM USE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR IN DIABETIC KIDNEY DISEASE

Saved in:

Bibliographic Details
Main Authors:	Jonghwan Jung, Hyejun Lee, Seon-Ho Ahn
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924025166
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN24-1511 THE CHANGE OF CLINICAL PARAMETERS AFTER USE OF SODIUMGLUCOSE COTRANSPORTER-2 INHIBITOR ACCORDING TO THE VALUES OF URINARY N-ACETYL-β-D-GLUCOSAMINIDASECREATININE RATIO IN PATIENTS DIABETIC KIDNEY DIS
by: Jonghwan Jung, et al.
Published: (2024-04-01)

Urinary bisphenol A and its substitutes exposure increased the risk of renal tubular injury (N-acetyl-β-d-glucosaminidase) in the general Taiwanese population
by: Yu-Jung Lin, et al.
Published: (2025-05-01)

Determination of n-acetyl β-d glucosaminidase enzyme activity in bovine milk for the early diagnosis of subclinical mastitis
by: Mehmet Nizamlıoğlu, et al.

Comparative proteomic analysis of plasma exosomes reveals the functional contribution of N-acetyl-alpha-glucosaminidase to Parkinson’s disease
by: Yuan Zhao, et al.
Published: (2025-10-01)

Preservation of Urinary Podocyte Markers in Diabetic Kidney Disease by Sodium-Glucose Cotransporter 2 Inhibitor Therapy
by: Chuanlei Li, et al.
Published: (2025-01-01)

Metabolic and microbial crossroads: Sodium-glucose cotransporter-2 inhibitors and urinary tract infections in (Asian) diabetes care
by: Rob E. Carpenter
Published: (2025-06-01)

Sodium Chloride Cotransporter in Hypertension
by: Annalisa Castagna, et al.
Published: (2024-11-01)

Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
by: A. M. Mkrtumyan, et al.
Published: (2021-09-01)

WCN24-790 COMPARATIVE ANALYSIS BETWEEN CLINICAL OR PATHOLOGICAL RISK FACTORS ASSOCIATED WITH DISEASE PROGRESSION IN ASIAN IMMUNOGLOBULIN A NEPHROPATHY PATIENTS
by: Jonghwan Jung, et al.
Published: (2024-04-01)

Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents
by: E. R. Radkevich, et al.
Published: (2025-05-01)

Sodium-glucose cotransporter 2 inhibitor for the treatment of diabetic nephropathy
by: Kong Ling-li, et al.
Published: (2021-01-01)

Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction
by: Nicia I. Profili, et al.
Published: (2025-03-01)

Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Kidney Disease and beyond
by: Zein Alabdin Hannouneh, et al.
Published: (2025-01-01)

Sodium Glucose Cotransporter Inhibition in Acute Heart Failure: An In-Depth Review
by: Joey A. Mercier, MD, FRCPC, et al.
Published: (2025-04-01)

Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors
by: Riber Fabián Donoso Noroña, et al.
Published: (2024-09-01)

WCN24-927 SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR FOR PREVENTION OF CONTRAST-INDUCED NEPHROPATHY: A SYSTEMATIC REVIEW AND META-ANALYSIS
by: Jayson Villavicencio, et al.
Published: (2024-04-01)

Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?—a cross sectional analysis of a nationwide Japanese claims database
by: Go Anan, et al.
Published: (2023-11-01)

Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema
by: Yoko Takatsuna, et al.
Published: (2020-01-01)

Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure
by: Yu. S. Ignatova, et al.
Published: (2024-02-01)

Perioperative euglycemic DKA: The YIN and YANG of sodium-glucose cotransporter 2 inhibitors
by: Shilpushp Bhosale, et al.
Published: (2025-01-01)

Timing and Adherence Matter for Sodium–Glucose Cotransporter‐2 Inhibitors in Heart Failure
by: Mehmet Birhan Yilmaz, et al.
Published: (2025-04-01)

Sodium-glucose cotransporter-1 inhibition and depression: A Mendelian randomization study
by: Gang Fan, et al.
Published: (2025-07-01)

Transporting Sodium-Glucose Cotransporter-2 Inhibitors to the African Continent: Challenges and Solutions
by: Valerie A. Luyckx, et al.
Published: (2024-03-01)

Effects of sodium-glucose cotransport-2 inhibitors treatment in patients with pulmonary hypertension
by: Mohammed Obeidat, et al.
Published: (2025-06-01)

Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic and Nondiabetic Renal Transplant Recipients
by: Lucie Maigret, et al.
Published: (2025-03-01)

Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation
by: Lisa M. Raven, MBBS, FRACP, et al.
Published: (2025-05-01)

Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update
by: Nicia I. Profili, et al.
Published: (2024-10-01)

Deciding for Therapy: Deciding for Peace of Mind
by: Janyne Sattler
Published: (2022-03-01)

Comparison of General Practice and Pharmaceutical Dispensing Data for Pharmacoepidemiological Research: Assessing the Risk of Urinary-Tract Infections with Sodium Glucose Cotransporter 2 Inhibitors for Diabetes
by: Svetla Gadzhanova, et al.
Published: (2018-01-01)

WCN25-1028 SODIUM GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS IN THE CONTROL OF ALBUMINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE, STUDY IN A MEXICAN CENTER
by: Alan Arzeta Popoca, et al.
Published: (2025-02-01)

WCN24-1550 ALDOSTERONE SYNTHASE INHIBITION WITH OR WITHOUT BACKGROUND SODIUM GLUCOSE COTRANSPORTER 2 INHIBITION IN CKD: A PHASE II CLINICAL TRIAL
by: Katherine Tuttle, et al.
Published: (2024-04-01)

Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares
by: N. B. Perepech, et al.
Published: (2021-07-01)

Ocular outcomes of the sodium-glucose cotransport inhibitors: A systematic review of cohort studies
by: Nathaniel Eraikhuemen, et al.
Published: (2025-04-01)

Effect of Sodium-Glucose Cotransporter Type 2 Inhibitors on The Development and Course of Atrial Fibrillation
by: D. A. Ishmaev, et al.
Published: (2025-01-01)

Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor
by: D. A. Lebedev, et al.
Published: (2020-10-01)

Role of sodium-glucose cotransporter 2 inhibitors in cardiovascular events in patients with heart failure
by: Eva Muja, et al.
Published: (2025-07-01)

The effect of sodium-glucose cotransporter 2 inhibition mediated by blood metabolites in lymphocytic leukemia
by: Diguang Wen, et al.
Published: (2025-11-01)

Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
by: Ashot A. Avagimyan, et al.
Published: (2025-02-01)

Unmasking of normocalcemic primary hyperparathyroidism after sodium-glucose cotransporter-2 inhibitor initiation
by: Christodoulos Dolapsakis, et al.
Published: (2025-01-01)

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
by: Muhammad Shahzeb Khan, et al.
Published: (2019-11-01)